Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06177197

Bronchiolitis Clearance Airways With Seaserum

Bronchiolitis Clearance Airways With Seaserum : a Doubled Blind Randomized Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
458 (estimated)
Sponsor
University Hospital, Brest · Academic / Other
Sex
All
Age
1 Month – 1 Year
Healthy volunteers
Not accepted

Summary

The objective of this study is to show that the use of electrodialyzed seawater reduces the duration (in days) of symptoms in acute infant bronchiolitis compared with the use of saline solution in infants aged 1 month to less than one year. B-CLASS study is a multicenter, prospective, controlled, randomized, double label blind.

Detailed description

This is a multicenter, prospective, controlled, randomized in 2 parrallel arms, double blind study. The Infants will be included after written informed consent will be obtained from the patients' parents or legally authorized representatives. Patients will be randomized either in the experimental group (electrodialyzed seawater) or in the control group (saline solution). Patients' parents will be call by phone at day 1, day 3, day 6, day 10 and day 21 after baseline.

Conditions

Interventions

TypeNameDescription
DEVICEPhysiomerInfants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort: * Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day. * Infant \> 6 months: one single dose administered per nostril 6 times a day.
DEVICESaline solutionInfants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort: * Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day. * Infant \> 6 months: one single dose administered per nostril 6 times a day.

Timeline

Start date
2025-01-10
Primary completion
2027-11-01
Completion
2028-12-01
First posted
2023-12-20
Last updated
2025-12-17

Locations

8 sites across 1 country: France

Source: ClinicalTrials.gov record NCT06177197. Inclusion in this directory is not an endorsement.